Breast Cancer Research and Treatment

, Volume 126, Issue 2, pp 333–343 | Cite as

Functional implication of TRAIL −716 C/T promoter polymorphism on its in vitro and in vivo expression and the susceptibility to sporadic breast tumor

  • Ranjana Pal
  • Sailesh Gochhait
  • Shilpi Chattopadhyay
  • Pawan Gupta
  • Neeraj Prakash
  • Gaurav Agarwal
  • Arun Chaturvedi
  • Nuzhat Husain
  • Syed Akhtar Husain
  • Rameshwar N. K. Bamezai
Preclinical study


Recently, TRAIL function has been elucidated beyond its known classical role of mediating cellular homeostasis and immune surveillance against transformed cells. Here, we show how CC genotype of −716 TRAIL promoter SNP rendered risk for sporadic breast cancer as compared to the CT and TT genotypes (P recessive model = 0.018, OR = 1.4, 95% CI = 1.1–1.9; P allele model = 0.010, OR = 1.3, 95% CI = 1.1–1.7). The in silico prediction of the introduction of core Sp1/Sp3-binding motif suggested the functional significance of the SNP variation. This functional implication was validated by luciferase assay in HeLa (P = 0.026), MCF-7 (P = 0.022), HepG2 (P = 0.024), and HT1080 (P = 0.030) cells and also by real-time expression studies on tumor tissues (P = 0.01), revealing the transcriptionally repressed status of −716 T when compared to −716 C allele. The SNP–SNP interactions reflected an enhanced protective effect of CT and TT genotypes with the protective genetic backgrounds of TP53-BRCA2 (P = 0.002, OR = 0.2, 95% CI = 0.1–0.6), IFNG (P = 0.0000002, OR = 0.3, 95% CI = 0.2–0.4), and common variant Casp8 (P = 0.0003, OR = 0.5, 95% CI = 0.3–0.7). Interestingly, a comparison with clinical parameters showed overrepresented CT and TT genotypes in progressing (P = 0.041) and ER/PR negative tumors (P = 0.024/0.006). This was explained by increased apoptotic index, calculated as a ratio of selected pro-apoptotic and anti-apoptotic gene expression profiles, in CC genotyped tumors, favoring either intrinsic (P = 0.008,0.018) or extrinsic (P = 0.025,0.217) pathway depending upon the ER/PR status. Our study reveals for the first time that a promoter SNP of TRAIL functionally modulates the gene and consequently its role in breast cancer pathogenesis, cautioning to consider the −716 TRAIL SNP status in patients undergoing TRAIL therapy.


TRAIL Polymorphism Apoptosis 



The authors would like to thank the patient and control subjects for their participation. RP is grateful to the Council of Scientific and Industrial Research, New Delhi, India, for the pre-doctoral fellowship. RB was supported by a research grant from the University Grants Commission to the National Centre of Applied Human Genetics and the University with Potential of Excellence projects.

Supplementary material

10549_2010_900_MOESM1_ESM.doc (110 kb)
Supplementary material 1 (DOC 92 kb)
10549_2010_900_MOESM2_ESM.jpg (23 kb)
Haploview graph showing LD between TRAIL locus −760/−716 and −716/−692 in patients and control (JPG 22 kb)
10549_2010_900_MOESM3_ESM.jpg (80 kb)
Real time PCR data of extrinsic and intrinsic apoptotic pathway genes with respect to TRAIL −716 genotype (JPG 80 kb)


  1. 1.
    Ashkenazi A (2008) Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 7(12):1001–1012PubMedCrossRefGoogle Scholar
  2. 2.
    Smyth MJ, Takeda K, Hayakawa Y, Peschon JJ, van den Brink MR, Yagita H (2003) Nature’s TRAIL—on a path to cancer immunotherapy. Immunity 18(1):1–6PubMedCrossRefGoogle Scholar
  3. 3.
    Yagita H, Takeda K, Hayakawa Y, Smyth MJ, Okumura K (2004) TRAIL and its receptors as targets for cancer therapy. Cancer Sci 95(10):777–783PubMedCrossRefGoogle Scholar
  4. 4.
    Schmaltz C, Alpdogan O, Kappel BJ, Muriglan SJ, Rotolo JA, Ongchin J, Willis LM, Greenberg AS, Eng JM, Crawford JM, Murphy GF, Yagita H, Walczak H, Peschon JJ, van den Brink MR (2002) T cells require TRAIL for optimal graft-versus-tumor activity. Nat Med 8(12):1433–1437PubMedCrossRefGoogle Scholar
  5. 5.
    Song K, Benhaga N, Anderson RL, Khosravi-Far R (2006) Transduction of tumor necrosis factor-related apoptosis-inducing ligand into hematopoietic cells leads to inhibition of syngeneic tumor growth in vivo. Cancer Res 66(12):6304–6311PubMedCrossRefGoogle Scholar
  6. 6.
    Park SY, Seol JW, Lee YJ, Cho JH, Kang HS, Kim IS, Park SH, Kim TH, Yim JH, Kim M, Billiar TR, Seol DW (2004) IFN-gamma enhances TRAIL-induced apoptosis through IRF-1. Eur J Biochem 271(21):4222–4228PubMedCrossRefGoogle Scholar
  7. 7.
    Iero M, Valenti R, Huber V, Filipazzi P, Parmiani G, Fais S, Rivoltini L (2008) Tumour-released exosomes and their implications in cancer immunity. Cell Death Differ 15(1):80–88PubMedCrossRefGoogle Scholar
  8. 8.
    Bosque A, Pardo J, Martinez-Lorenzo MJ, Iturralde M, Marzo I, Pineiro A, Alava MA, Naval J, Anel A (2005) Down-regulation of normal human T cell blast activation: roles of APO2L/TRAIL, FasL, and c-FLIP, Bim, or Bcl-x isoform expression. J Leukoc Biol 77(4):568–578PubMedCrossRefGoogle Scholar
  9. 9.
    Renshaw SA, Parmar JS, Singleton V, Rowe SJ, Dockrell DH, Dower SK, Bingle CD, Chilvers ER, Whyte MK (2003) Acceleration of human neutrophil apoptosis by TRAIL. J Immunol 170(2):1027–1033PubMedGoogle Scholar
  10. 10.
    Giovarelli M, Musiani P, Garotta G, Ebner R, Di Carlo E, Kim Y, Cappello P, Rigamonti L, Bernabei P, Novelli F, Modesti A, Coletti A, Ferrie AK, Lollini PL, Ruben S, Salcedo T, Forni G (1999) A “stealth effect”: adenocarcinoma cells engineered to express TRAIL elude tumor-specific and allogeneic T cell reactions. J Immunol 163(9):4886–4893PubMedGoogle Scholar
  11. 11.
    Rabinovich GA, Gabrilovich D, Sotomayor EM (2007) Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25:267–296PubMedCrossRefGoogle Scholar
  12. 12.
    Igney FH, Krammer PH (2002) Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol 71(6):907–920PubMedGoogle Scholar
  13. 13.
    Johnstone RW, Frew AJ, Smyth MJ (2008) The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 8(10):782–798PubMedCrossRefGoogle Scholar
  14. 14.
    Falschlehner C, Emmerich CH, Gerlach B, Walczak H (2007) TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol 39(7–8):1462–1475PubMedCrossRefGoogle Scholar
  15. 15.
    Ishimura N, Isomoto H, Bronk SF, Gores GJ (2006) Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. Am J Physiol Gastrointest Liver Physiol 290(1):G129–G136PubMedCrossRefGoogle Scholar
  16. 16.
    Tokumoto Y, Horimoto K, Miyake J (2009) TRAIL inhibited the cyclic AMP responsible element mediated gene expression. Biochem Biophys Res Commun 381(4):533–536PubMedCrossRefGoogle Scholar
  17. 17.
    Solier S, Sordet O, Kohn KW, Pommier Y (2009) Death receptor-induced activation of the Chk2- and histone H2AX-associated DNA damage response pathways. Mol Cell Biol 29(1):68–82PubMedCrossRefGoogle Scholar
  18. 18.
    Kuribayashi K, Krigsfeld G, Wang W, Xu J, Mayes PA, Dicker DT, Wu GS, El-Deiry WS (2008) TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death. Cancer Biol Ther 7(12):2034–2038PubMedCrossRefGoogle Scholar
  19. 19.
    Takimoto R, El-Deiry WS (2000) Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene 19(14):1735–1743PubMedCrossRefGoogle Scholar
  20. 20.
    Liu X, Yue P, Khuri FR, Sun SY (2004) p53 upregulates death receptor 4 expression through an intronic p53 binding site. Cancer Res 64(15):5078–5083PubMedCrossRefGoogle Scholar
  21. 21.
    Herzer K, Grosse-Wilde A, Krammer PH, Galle PR, Kanzler S (2008) Transforming growth factor-beta-mediated tumor necrosis factor-related apoptosis-inducing ligand expression and apoptosis in hepatoma cells requires functional cooperation between Smad proteins and activator protein-1. Mol Cancer Res 6(7):1169–1177PubMedCrossRefGoogle Scholar
  22. 22.
    Xu J, Zhou JY, Wu GS (2006) Tumor necrosis factor-related apoptosis-inducing ligand is required for tumor necrosis factor alpha-mediated sensitization of human breast cancer cells to chemotherapy. Cancer Res 66(20):10092–10099PubMedCrossRefGoogle Scholar
  23. 23.
    Sohn BH, Moon HB, Kim TY, Kang HS, Bae YS, Lee KK, Kim SJ (2001) Interleukin-10 up-regulates tumour-necrosis-factor-alpha-related apoptosis-inducing ligand (TRAIL) gene expression in mammary epithelial cells at the involution stage. Biochem J 360(Pt 1):31–38PubMedCrossRefGoogle Scholar
  24. 24.
    Akira S (1997) IL-6-regulated transcription factors. Int J Biochem Cell Biol 29(12):1401–1418PubMedCrossRefGoogle Scholar
  25. 25.
    Yan X, Xu L, Qi J, Liang X, Ma C, Guo C, Zhang L, Sun W, Zhang J, Wei X, Gao L (2009) sTRAIL levels and TRAIL gene polymorphisms in Chinese patients with fatty liver disease. Immunogenetics 61(8):551–556PubMedCrossRefGoogle Scholar
  26. 26.
    Kikuchi S, Miyagishi R, Fukazawa T, Yabe I, Miyazaki Y, Sasaki H (2005) TNF-related apoptosis inducing ligand (TRAIL) gene polymorphism in Japanese patients with multiple sclerosis. J Neuroimmunol 167(1–2):170–174PubMedCrossRefGoogle Scholar
  27. 27.
    Weber A, Wandinger KP, Mueller W, Aktas O, Wengert O, Grundstrom E, Ehrlich S, Windemuth C, Kuhlmann T, Wienker T, Bruck W, Zipp F (2004) Identification and functional characterization of a highly polymorphic region in the human TRAIL promoter in multiple sclerosis. J Neuroimmunol 149(1–2):195–201PubMedCrossRefGoogle Scholar
  28. 28.
    Gray HL, Sorensen EL, Hunt JS, Ober C (2001) Three polymorphisms in the 3’ UTR of the TRAIL (TNF-related apoptosis-inducing ligand) gene. Genes Immun 2(8):469–470PubMedCrossRefGoogle Scholar
  29. 29.
    Wang Q, Ji Y, Wang X, Evers BM (2000) Isolation and molecular characterization of the 5′-upstream region of the human TRAIL gene. Biochem Biophys Res Commun 276(2):466–471PubMedCrossRefGoogle Scholar
  30. 30.
    Unoki M, Furuta S, Onouchi Y, Watanabe O, Doi S, Fujiwara H, Miyatake A, Fujita K, Tamari M, Nakamura Y (2000) Association studies of 33 single nucleotide polymorphisms (SNPs) in 29 candidate genes for bronchial asthma: positive association a T924C polymorphism in the thromboxane A2 receptor gene. Hum Genet 106(4):440–446PubMedCrossRefGoogle Scholar
  31. 31.
    Gochhait S, Bukhari SI, Bairwa N, Vadhera S, Darvishi K, Raish M, Gupta P, Husain SA, Bamezai RN (2007) Implication of BRCA2–26 > A 5′ untranslated region polymorphism in susceptibility to sporadic breast cancer and its modulation by p53 codon 72 Arg > Pro polymorphism. Breast Cancer Res 9(5):R71PubMedCrossRefGoogle Scholar
  32. 32.
    Gupta V, Arora R, Ranjan A, Bairwa NK, Malhotra DK, Udhayasuriyan PT, Saha A, Bamezai R (2005) Gel-based nonradioactive single-strand conformational polymorphism and mutation detection: limitations and solutions. Methods Mol Biol 291:247–261PubMedGoogle Scholar
  33. 33.
    Xiao W, Oefner PJ (2001) Denaturing high-performance liquid chromatography: a review. Hum Mutat 17(6):439–474PubMedCrossRefGoogle Scholar
  34. 34.
    Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3 (7):RESEARCH0034Google Scholar
  35. 35.
    Vegran F, Boidot R, Oudin C, Riedinger JM, Bonnetain F, Lizard-Nacol S (2006) Overexpression of caspase-3s splice variant in locally advanced breast carcinoma is associated with poor response to neoadjuvant chemotherapy. Clin Cancer Res 12(19):5794–5800PubMedCrossRefGoogle Scholar
  36. 36.
    Yu B, Datta PK, Bagchi S (2003) Stability of the Sp3-DNA complex is promoter-specific: Sp3 efficiently competes with Sp1 for binding to promoters containing multiple Sp-sites. Nucleic Acids Res 31(18):5368–5376PubMedCrossRefGoogle Scholar
  37. 37.
    Kumar AP, Butler AP (1997) Transcription factor Sp3 antagonizes activation of the ornithine decarboxylase promoter by Sp1. Nucleic Acids Res 25(10):2012–2019PubMedCrossRefGoogle Scholar
  38. 38.
    Geltinger C, Hortnagel K, Polack A (1996) TATA box and Sp1 sites mediate the activation of c-myc promoter P1 by immunoglobulin kappa enhancers. Gene Expr 6(2):113–127PubMedGoogle Scholar
  39. 39.
    Birnbaum MJ, van Wijnen AJ, Odgren PR, Last TJ, Suske G, Stein GS, Stein JL (1995) Sp1 trans-activation of cell cycle regulated promoters is selectively repressed by Sp3. Biochemistry 34(50):16503–16508PubMedCrossRefGoogle Scholar
  40. 40.
    Majello B, De Luca P, Suske G, Lania L (1995) Differential transcriptional regulation of c-myc promoter through the same DNA binding sites targeted by Sp1-like proteins. Oncogene 10(9):1841–1848PubMedGoogle Scholar
  41. 41.
    Hagen G, Muller S, Beato M, Suske G (1992) Cloning by recognition site screening of two novel GT box binding proteins: a family of Sp1 related genes. Nucleic Acids Res 20(21):5519–5525PubMedCrossRefGoogle Scholar
  42. 42.
    Hagen G, Muller S, Beato M, Suske G (1994) Sp1-mediated transcriptional activation is repressed by Sp3. EMBO J 13(16):3843–3851PubMedGoogle Scholar
  43. 43.
    Kingsley C, Winoto A (1992) Cloning of GT box-binding proteins: a novel Sp1 multigene family regulating T-cell receptor gene expression. Mol Cell Biol 12(10):4251–4261PubMedGoogle Scholar
  44. 44.
    Safe S, Abdelrahim M (2005) Sp transcription factor family and its role in cancer. Eur J Cancer 41(16):2438–2448PubMedCrossRefGoogle Scholar
  45. 45.
    Li L, He S, Sun JM, Davie JR (2004) Gene regulation by Sp1 and Sp3. Biochem Cell Biol 82(4):460–471PubMedCrossRefGoogle Scholar
  46. 46.
    Resendes KK, Rosmarin AG (2004) Sp1 control of gene expression in myeloid cells. Crit Rev Eukaryot Gene Expr 14(3):171–181PubMedCrossRefGoogle Scholar
  47. 47.
    Bouwman P, Philipsen S (2002) Regulation of the activity of Sp1-related transcription factors. Mol Cell Endocrinol 195(1–2):27–38PubMedCrossRefGoogle Scholar
  48. 48.
    Black AR, Black JD, Azizkhan-Clifford J (2001) Sp1 and kruppel-like factor family of transcription factors in cell growth regulation and cancer. J Cell Physiol 188(2):143–160PubMedCrossRefGoogle Scholar
  49. 49.
    Suske G (1999) The Sp-family of transcription factors. Gene 238(2):291–300PubMedCrossRefGoogle Scholar
  50. 50.
    Lania L, Majello B, De Luca P (1997) Transcriptional regulation by the Sp family proteins. Int J Biochem Cell Biol 29(12):1313–1323PubMedCrossRefGoogle Scholar
  51. 51.
    Saha A, Dhir A, Ranjan A, Gupta V, Bairwa N, Bamezai R (2005) Functional IFNG polymorphism in intron 1 in association with an increased risk to promote sporadic breast cancer. Immunogenetics 57(3–4):165–171PubMedCrossRefGoogle Scholar
  52. 52.
    Sun T, Gao Y, Tan W, Ma S, Shi Y, Yao J, Guo Y, Yang M, Zhang X, Zhang Q, Zeng C, Lin D (2007) A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. Nat Genet 39(5):605–613PubMedCrossRefGoogle Scholar
  53. 53.
    Yu Y, Liu S, Wang W, Song W, Zhang M, Zhang W, Qin Z, Cao X (2002) Involvement of tumour necrosis factor-alpha-related apoptosis-inducing ligand in enhanced cytotoxicity of lipopolysaccharide-stimulated dendritic cells to activated T cells. Immunology 106(3):308–315PubMedCrossRefGoogle Scholar
  54. 54.
    Zhao S, Asgary Z, Wang Y, Goodwin R, Andreeff M, Younes A (1999) Functional expression of TRAIL by lymphoid and myeloid tumour cells. Br J Haematol 106(3):827–832PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • Ranjana Pal
    • 1
  • Sailesh Gochhait
    • 1
  • Shilpi Chattopadhyay
    • 1
  • Pawan Gupta
    • 2
  • Neeraj Prakash
    • 3
  • Gaurav Agarwal
    • 4
  • Arun Chaturvedi
    • 5
  • Nuzhat Husain
    • 5
  • Syed Akhtar Husain
    • 6
  • Rameshwar N. K. Bamezai
    • 1
    • 7
  1. 1.National Centre of Applied Human Genetics, School of Life SciencesJawaharlal Nehru UniversityNew DelhiIndia
  2. 2.Dharamshila Cancer Hospital and Research CentreDelhiIndia
  3. 3.Rajiv Gandhi Cancer Institute and Research CenterNew DelhiIndia
  4. 4.Sanjay Gandhi Postgraduate Institute of Medical SciencesLucknowIndia
  5. 5.Chhatrapati Shahuji Maharaj Medical UniversityLucknowIndia
  6. 6.Human Genetics Laboratory, Department of BiosciencesJamia Milia IslamiaNew DelhiIndia
  7. 7.SMVDUKatraJammu and KashmirIndia

Personalised recommendations